

# Chee Khoon Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8596443/publications.pdf>

Version: 2024-02-01

62  
papers

6,808  
citations

236612

25  
h-index

114278

63  
g-index

64  
all docs

64  
docs citations

64  
times ranked

8318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. <i>Lung Cancer</i> , 2022, 163, 14-18.	0.9	2
2	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	2.0	15
3	Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 1574-1583.	2.0	14
4	Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 40-48.	0.9	7
5	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1793-1799.	1.1	6
6	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
7	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 170, 169-178.	1.3	2
8	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
9	Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 893-902.	1.1	2
10	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021, 127, 2432-2441.	2.0	14
11	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2021, 154, 113-117.	0.9	5
12	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. <i>European Journal of Cancer</i> , 2021, 148, 251-259.	1.3	2
13	Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 930-936.	0.5	11
14	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
15	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	1.3	9
16	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 508-514.	0.5	23
17	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020, 59, 20-27.	0.8	3
18	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials. <i>JAMA Network Open</i> , 2020, 3, e2011809.	2.8	33
20	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512.	0.8	54
21	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	1.1	4
22	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	1.3	17
23	Reply to Q. Wu et al.. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 191-191.	0.7	1
24	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016). <i>British Journal of Cancer</i> , 2019, 121, 904-911.	2.9	9
25	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 271-278.	1.1	31
26	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	2.9	17
27	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 141-152.	0.7	54
28	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
29	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800.	0.5	17
30	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 841-849.	0.8	423
31	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. <i>Medical Journal of Australia</i> , 2018, 209, 354-355.	0.8	35
32	Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. <i>Breast</i> , 2018, 41, 82-88.	0.9	2
33	When do patient reported quality of life indicators become prognostic in breast cancer?. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 13.	1.0	10
34	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878850.	1.4	4
35	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	3.4	36
36	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. <i>JAMA Oncology</i> , 2018, 4, 1138.	3.4	2

#	ARTICLE	IF	CITATIONS
37	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	196
38	Osimertinib or Platinum+Pemetrexed in EGFR T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 629-640.	13.9	2,631
39	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 633-643.	0.5	122
40	A most malignant malady™: a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma. <i>Internal Medicine Journal</i> , 2017, 47, 1215-1216.	0.5	1
41	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	0.6	21
42	Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	1
43	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 403-407.	0.5	653
44	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 936-944.	0.8	17
45	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24.	0.6	39
46	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	1.3	23
47	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965.	0.8	280
48	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	0.8	154
49	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 731-741.	2.3	27
50	A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, 937-943.	0.6	32
51	Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. <i>SpringerPlus</i> , 2013, 2, 391.	1.2	14
52	Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 595-605.	3.0	469
53	Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. <i>Clinical Cancer Research</i> , 2012, 18, 3188-3196.	3.2	63
54	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2675-2682.	0.8	198

#	ARTICLE	IF	CITATIONS
55	A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 467-476.	1.1	12
56	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	3.0	33
57	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 1144-1150.	2.9	32
58	Carboplatin and paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 360-365.	2.9	28
59	Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. <i>British Journal of Cancer</i> , 2010, 102, 1341-1347.	2.9	39
60	Historical cross-trial comparisons for competing treatments in advanced breast cancer – An empirical analysis of bias. <i>European Journal of Cancer</i> , 2010, 46, 541-548.	1.3	9
61	Molecular biomarkers to individualise treatment: assessing the evidence. <i>Medical Journal of Australia</i> , 2009, 190, 631-636.	0.8	23
62	When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis. <i>World Journal of Surgical Oncology</i> , 2009, 7, 8.	0.8	11